![Stocks To Watch Today (23 Apr 2024): Gallantt Metal Hits New All-Time High, TECHNOE Brews 52-Week High & More](https://stockpricearchive.com/wp-content/uploads/2024/04/tue-23-apr-2024-stocks-to-watch-150x150.webp)
Home / Share Price Target / Shukraphar
Shukra Pharmaceuticals Share Price Target 2024, 2025, 2026 to 2039 With Charts
Shukra Pharmaceuticals Limited | |||
![]() | Symbol: SHUKRAPHAR | ||
Price: ₹61.85 | |||
Exchange: BSE | |||
-> |
Show Table of Contents
Table of Contents
- 0.1: Shukra Pharmaceuticals Financial Performance
- 0.1.1: Is Shukra Pharmaceuticals A Good Buy For Long Term?
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Shukra Pharmaceuticals Share Price Target For 2024
- 1.1.1: Shukra Pharmaceuticals Share Price Target Table For 2024
- 1.1.2: Summary: Shukra Pharmaceuticals Share Price Prediction For 2024
- 1.2: Shukra Pharmaceuticals Share Price Target For 2025
- 1.2.1: Shukra Pharmaceuticals Share Price Target Table For 2025
- 1.2.2: Summary: Shukra Pharmaceuticals Share Price Prediction For 2025
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Shukra Pharmaceuticals Long Term Share Price Prediction Chart From 2024, 2025, 2026 to 2039
- 2.2: Shukra Pharmaceuticals Share Price Target Table From 2024, 2025, 2026 to 2039
- 3: Shukra Pharmaceuticals Past Performance
Advertisement
Shukra Pharmaceuticals Financial Performance
Metric | Value | Description |
---|---|---|
Market Capital | 18.51 Crore | Market valuation of Shukra Pharmaceuticals's shares. |
Revenue (TTM) | 58.83 Crore | Total revenue generated by Shukra Pharmaceuticals over the past twelve months. |
Net Income (TTM) | +4.4 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
Operating Margin | 7.98% | Income from operations as a percentage of revenue, before taxes and interest. |
Profit Margin | 22.97% | Net income as a percentage of revenue, after all expenses. |
Revenue Growth (Quarterly) | -23.33% | Change in revenue compared to the previous quarter. |
Debt-to-Equity (D/E) Ratio | 0.05 | Company's total debt divided by total shareholder equity. |
Total Debt | 2.3 Crore | Sum of Shukra Pharmaceuticals's current & long-term financial obligations. |
Is Shukra Pharmaceuticals A Good Buy For Long Term?
Shukra Pharmaceuticals, with a market cap of 17.42 Crore, has recently reported a revenue of 58.83 Crore and a net profit of 4.4 Crore. While the company has experienced a quarterly revenue decline of 23.33%, it maintains a healthy profit margin of 22.97%. Despite a debt of 2.3 Crore, Shukra Pharmaceuticals has delivered impressive long-term returns, including a remarkable 1220.16% over the past 3 years. Considering these factors, the stock appears to be an average buy for long-term investors seeking moderate growth potential.
To predict the Shukra Pharmaceuticals's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Shukra Pharmaceuticals Share Price Target For 2024
![Shukra Pharmaceuticals Targets For 2024 Chart](/wp-content/uploads/nip_uploads/charts/shukraphar_thisyear_20240830.webp)
The line chart displays the monthly closing prices of Shukra Pharmaceuticals with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Shukra Pharmaceuticals shares in 2024, see the table below.
Advertisement
Shukra Pharmaceuticals Share Price Target Table For 2024
Shukra Pharmaceuticals's Levels | Value | Reason/Importance |
---|---|---|
2024 Target 3 | 67.64 (+9.36%) | Price Action: 26 Aug 2024 High |
2024 Target 2 | 66.40 (+7.35%) | Custom Fibonacci Extension Lvl 23.6% |
2024 Target 1 | 65.65 (+6.14%) | Price Action: 05 Sep 2024 High |
Current Price | 61.85 | Shukra Pharmaceuticals's 1 share price as of Fri 06 Sep 2024 |
Stop Loss 1 | 59.77 (-3.37%) | Price Action: 21 Aug 2024 Low |
Stop Loss 2 | 59.02 (-4.58%) | Price Action: 22 Aug 2024 Low |
Stop Loss 3 | 57.60 (-6.88%) | Price Action: Feb 2014 Low |
Summary: Shukra Pharmaceuticals Share Price Prediction For 2024
In summary, Shukra Pharmaceuticals has declined by ₹-61.90, recording a notable -50.02% decrease from 1st January 2024 to 06 Sep 2024. Despite the setback, our analysis of Shukra Pharmaceuticals for 2024 predicts an additional rise of 6.14% to 9.36% by the end of 2024 with three potential targets T1: 65.65, T2: 66.40, T3: 67.64. Stop Loss at SL1: 59.77, SL2: 59.02, SL3: 57.60.
Shukra Pharmaceuticals has a 52-week high of ₹388.00, acting as a crucial resistance level - a ceiling that could challenge further price increase. Conversely, it has a 52-week low of ₹59.02, a critical support level - think of this as a safety net where the price might stop falling.
After looking at 2024's share price prediction, let's now check what 2025 might hold for Shukra Pharmaceuticals.
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Shukra Pharmaceuticals Share Price Target For 2025
![Shukra Pharmaceuticals Targets For 2025 Chart](/wp-content/uploads/nip_uploads/charts/shukraphar_nextyear_20240830.webp)
The line chart displays the monthly closing prices of Shukra Pharmaceuticals with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Shukra Pharmaceuticals shares in 2025, see the table below.
Advertisement
Shukra Pharmaceuticals Share Price Target Table For 2025
Shukra Pharmaceuticals's Levels | Value | Reason/Importance |
---|---|---|
2025 Target 3 | 281.99 (+355.92%) | Price Action: Chart |
2025 Target 2 | 276.73 (+347.42%) | Price Action: Chart |
2025 Target 1 | 273.99 (+342.99%) | Custom Fibonacci Extension Lvl 64.9% |
Current Price | 61.85 | Shukra Pharmaceuticals's 1 share price as of Fri 06 Sep 2024 |
Stop Loss 1 | 9.75 (-84.24%) | Price Action: Chart |
Stop Loss 2 | 9.65 (-84.4%) | Price Action: Chart |
Stop Loss 3 | 9.48 (-84.68%) | Price Action: Chart |
Summary: Shukra Pharmaceuticals Share Price Prediction For 2025
In summary, Shukra Pharmaceuticals has declined by ₹-61.90, recording a notable -50.02% decrease from 1st January 2024 to 06 Sep 2024. Despite the setback, our analysis of Shukra Pharmaceuticals for 2025 predicts an additional rise of 342.99% to 355.92% by the end of 2025 with three potential targets T1: 273.99, T2: 276.73, T3: 281.99. Stop Loss at SL1: 9.75, SL2: 9.65, SL3: 9.48.
Shukra Pharmaceuticals has a All-Time high of ₹388.00, acting as a crucial resistance level - a ceiling that could challenge further price increase. Conversely, it has a 52-week low of ₹59.02, a critical support level - think of this as a safety net where the price might stop falling.
After looking at 2024's and 2025's share price prediction, you might wonder what are short term targets for Shukra Pharmaceuticals, we have created a specific page for that check here: Shukra Pharmaceuticals Share Price Target For Tomorrow & Next Week
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Shukra Pharmaceuticals Long Term Share Price Prediction Chart From 2024, 2025, 2026 to 2039
![Shukra Pharmaceuticals Targets Chart 2024, 2025, 2026 to 2039](/wp-content/uploads/nip_uploads/charts/shukraphar_15years_20240830.webp)
This chart presents a detailed projection of Shukra Pharmaceuticals share price predictions from 2024, 2025, 2026 to 2039. This share price Prediction represents a CAGR of 12.24% over the next 15 years.
For complete year by year Shukra Pharmaceuticals long term share price target from 2024, 2025 to 2039 check the below table.
Shukra Pharmaceuticals Share Price Target Table From 2024, 2025, 2026 to 2039
Year | Shukra Pharmaceuticals Target | YoY Change % |
---|---|---|
2024 | ₹61.85 | [Current Price] |
2024 | ₹82.23 | 32.95% |
2025 | ₹96.63 | 17.51% |
2026 | ₹85.63 | -11.39% |
2027 | ₹68.27 | -20.28% |
2028 | ₹58.37 | -14.51% |
2029 | ₹89.28 | 52.95% |
2030 | ₹71.68 | -19.72% |
2031 | ₹67.27 | -6.16% |
2032 | ₹272.08 | 304.47% |
2033 | ₹308.83 | 13.5% |
2034 | ₹341.51 | 10.58% |
2035 | ₹319.69 | -6.39% |
2036 | ₹371.49 | 16.2% |
2037 | ₹348.9 | -6.09% |
2038 | ₹391.35 | 12.16% |
2039 | ₹414.26 | 5.85% |
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Shukra Pharmaceuticals Past Performance
![SHUKRAPHAR main](/wp-content/uploads/nip_uploads/charts/SHUKRAPHAR_main.webp)
- In 2012, Shukra Pharmaceuticals opening price was ₹164
- As of Fri 06 Sep 2024 the price stands at ₹61.85.
- This represents a Compound Annual Growth Rate (CAGR) of -7.23%.
- In 12 years, an investment of 10,000 would have become ₹3,771.34.
As we wrap up, we hope you like our study on Shukra Pharmaceuticals share price predictions, please kindly note that these forecasts are based on technical analysis, past trends, and machine learning models. They are for educational purposes only, not investment advice.
Show Methodology We Use
Methodology Behind the Prediction
The share price predictions present on our site are derived from a robust model that incorporates multiple economic indicators, technical indicators, company performance metrics, and industry-specific factors.
We have historical share price data of all stocks for which we present targets, so we analyse historical trends from those past data and overlay them with projected market conditions to estimate future share prices of a stock.
- Shukra Pharmaceuticals Share Price History
- Shukra Pharmaceuticals Price Target Tomorrow
- Shukra Pharmaceuticals Dividend History
Disclaimer: Information is provided 'as is' and solely for informational and educational purposes, not for trading purposes or advice. We highly recommend to do your own research before making any investment.